Treatment and management of psoriasis with nail involvement: A focus on biologic therapy

Dermatology

Volumn 221, Issue SUPPL. 1, 2010, Pages 29-42

  Langley, Richard G ^a   Daudén, Esteban ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Biologics; Nail disease; Nail psoriasis; Psoriasis, treatment

Indexed keywords

ALEFACEPT; ALLOPURINOL; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; ETANERCEPT; ETRETIN; ETRETINATE; FLUOROURACIL; GLUCOCORTICOID; INFLIXIMAB; METHOXSALEN; SALAZOSULFAPYRIDINE; SALICYLIC ACID; TAZAROTENE; TRIAMCINOLONE ACETONIDE; USTEKINUMAB;

ANXIETY; CLINICAL FEATURE; DEPRESSION; EVENING DOSAGE; HUMAN; MENTAL STRESS; NAIL DISEASE; PATIENT SATISFACTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; RADIOTHERAPY; REVIEW; BIOLOGICAL THERAPY; DISEASE MANAGEMENT; NAIL DISEASES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BIOLOGICAL THERAPY; DISEASE MANAGEMENT; HUMANS; NAIL DISEASES; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 77956018974     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316179     Document Type: Review

References (75)

1. Jiaravuthisan MM, Sasseville D, Vender RB, Murphy F, Muhn CY: Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27.
2. Sanchez-Regna M, Umbert P: Diagnosis and management of nail psoriasis. Actas Dermosifiliogr 2008; 99: 34-43.
3. Samman PD, Fenton DA: The Nails in Disease, ed 5. London, Butterworth-Heinemann Ltd., 1994.
4. Gregoriou S, Kalogeromitros D, Kosionis N, Gkouvi A, Rigopoulos D: Treatment options for nail psoriasis. Expert Rev Dermatol 2008; 3: 339-344.
5. Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP: Extended report: nail disease in psoriatic arthritis - clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004; 43: 790-794.
6. Lawry M: Biological therapy and nail psoriasis. Dermatol Ther 2007; 20: 60-67.
7. De Jong EMGJ, Seegers BAMPA, Gulinck MK, Boezeman JBM, van de Kerkhof PCM: Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193: 300-303.
8. Helliwell P, Marchesoni A, Peters M, Barker M, Wright V: A re-evaluation of the osteoarticular manifestations of psoriasis. Br J Rheumatol 1991; 30: 339-345.
9. Landells I, MacCallum C, Khraishi M: The role of the dermatologist in identification and treatment of the early stages of psoriatic arthritis. Skin Therapy Lett 2008; 13: 4-8.
10. Salomon J, Szepietowski JC, Proniewicz A: Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003; 7: 317-321.
11. Wilson FC, Icen M, Crowson CS, et al: Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population- based study. Arthritis Rheum 2009; 61: 233-239.
12. Luger TA, Barker J, Lambert J, et al: Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2009; 23: 896-904.
13. Guero S, Guichard S, Fraitag SR: Ligamentary structure of the base of the nail. Surg Radiol Anat 1994; 16: 47-52.
14. Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, McGonagle D: The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis - a high-resolution MRI and histological study. Rheumatology (Oxford) 2007; 46: 253-256.
15. Baran R, Dawber RPR (eds): Diseases of the Nail and Their Management. Oxford, Blackwell Science, 1984.
16. De Berker DAR: Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357-362.
17. Tosti A, Piraccini BM, Cameli N, et al: Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: 655-659.
18. Rigopoulos D, Ioannides D, Prastitis N, Katsambas A: Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002; 82: 140.
19. Tzung TY, Chen CY, Yang CY, et al: Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88: 279-280.
20. Zakeri M, Valikhani M, Mortazavi H, Barzegari M: Topical calcipotriol therapy in nail psoriasis: a study of 24 cases. Dermatol Online J 2005; 11: 5.
21. Scher RK, Stiller M, Zhu YI: Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355-358.
22. Rigopoulos D, Gregoriou S, Katsambas A: Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol 2007; 87: 167-189.
23. Bianchi L, Soda R, Diluvio L, Chimenti S: Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003; 149: 207-209.
24. Cannavo SP, Guarneri F, Vaccaro M, Borgia F, Guarneri B: Treatment of psoriatic nails with topical cyclosporine: a prospective, randomized placebo-controlled study. Dermatology 2003; 206: 152-156.
25. De Berker DAR, Lawrence CM: A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 138: 90-95.
26. Gerstein W: Psoriasis and lichen planus of nails. Treatment with triamcinolone. Arch Dermatol 1962; 86: 419-421.
27. Abell E, Samman PD: Intradermal triamcinolone treatment of nail dystrophies. Br J Dermatol 1973; 89: 191-197.
28. Bleeker JJ: Intralesional triamcinolone acetonide using the Port-O-Jet and needle injections in localized dermatoses. Br J Dermatol 1974; 91: 97-101.
29. Peachey RD, Pye RJ, Harman RR: The treatment of psoriatic nail dystrophy with intradermal steroid injections. Br J Dermatol 1976; 95: 75-78.
30. Marx JL, Scher RK: Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116: 1023-1024.
31. Handfield-Jones SE, Boyle J, Harman RR: Local PUVA treatment for nail psoriasis. Br J Dermatol 1987; 116: 280-281.
32. Yu RCH, King CM: A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Derm Venereol 1992; 72: 134-136.
33. Finnerty EF: Successful treatment of psoriasis of the nails. Cutis 1979; 23: 43-44.
34. Lindelöf B: Psoriasis of the nails treated with Grenz rays: a double-blind bilateral trial. Acta Derm Venereol 1989; 69: 80-82.
35. Kwang TY, Nee TS, Seng KT: A therapeutic study of nail psoriasis using electron beams. Acta Derm Venereol 1995; 75: 90.
36. Levell NJ, Shuster S, Munro CS, Friedmann PS: Remission of ordinary psoriasis following a short clearance course of cyclosporin. Acta Derm Venereol 1995; 75: 65-69.
37. Mahrle G, Schulze HJ, Färber L, Weidinger G, Steigleder GK: Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78-88.
38. Tosti A, Ricotti C, Romanelli P, et al: Evaluation of the efficacy of acitretin therapy for nail psoriasis. Arch Dermatol 2009; 145: 269-271.
39. Syuto T, Abe M, Ishibuchi H, Ishikawa O: Successful treatment of psoriatic nails with low-dose cyclosporine administration. Eur J Dermatol 2007; 17: 248-249.
40. Feliciani C, Zampetti A, Forleo P, et al: Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg 2004; 8: 122-125.
41. Van den Bosch F, Reece R, Behrens F, et al: Clinically important nail psoriasis improvements are achieved with adalimumab (Humira- ): results from a large open-label prospective study (STEREO). Ann Rheum Dis 2007; 66(suppl II):421.
42. Korman N, Rico MJ: Multiple courses of alefacept for the treatment of psoriatic nail disease in patients with chronic plaque psoriasis. J Am Acad Dermatol 2007; 56:AB114, P1510.
43. Korver JEM, Langewouters AMG, Van de Kerkhof PCM, Pasch MC: Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252-1255.
44. Carr D, Tusa MG, Carroll CL, et al: Open label trial of alefacept in palmoplantar pustular psoriasis. J Dermatol Treat 2008; 19: 97-100.
45. Parrish CA, Sobera JO, Robbins CM, et al: Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol 2006; 5: 339-340.
46. Pariser D, Paller AS, Sigfried E, et al: Effect of etanercept treatment on skin and nail psoriasis symptoms in children and adolescents. EADV 2008, poster P448.
47. Rich P, Guzzo C, Wang Y, Gordon K: Improvement in nail psoriasis with ustekinumab, a new anti-IL-12/23p40 monoclonal antibody: results from a phase 3 trial. AAD 2008.
48. Rich P, Griffiths CEM, Reich K, et al: Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008; 58: 224-231.
49. Bianchi L, Bergamin A, de Felice C, Capriotti E, Chimenti S: Remission and time of resolution of nail psoriasis during infliximab therapy. J Am Acad Dermatol 2005; 52: 736-737.
50. Hussain W, Coulson I, Owen C: Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008; 33: 520-522.
51. Rigopoulos D, Gregoriou S, Stratigos A, et al: Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008; 159: 453-456.
52. Reich K, Nestle FO, Papp K, et al: Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374.
53. Saraceno R, Bianchi L, Pietroleonardo L, et al: Remission and time of resolution of nail psoriasis: a comparison among antitumour necrosis factor-alpha inhibitors. Br J Dermatol 2008; 159: 1418, P47.
54. Gudjonsson JE, Karason A, Runarsdottir EH, et al: Distinct clinical differences between HLA-Cw * 0602 positive and negative psoriasis patients - an analysis of 1019 HLAC- and HLA-B-typed patients. J Invest Dermatol 2006; 126: 740-745.
55. Enbrel Summary of Product Characteristics (SPC).
56. Abbott Laboratories Limited: Humira pen and syringe. Summary of product characteristics. September 2008.
57. Schering-Plough Ltd: Remicade 100 mg powder for concentrate for solution for infusion. Summary of product characteristics. August 2008.
58. Rallis E, Stavropoulou E, Rigopoulos D, Verros C: Rapid response of nail psoriasis to etanercept. J Rheumatol 2008; 35: 544-545.
59. Reich K, Griffiths CEM: The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 2008; 300: 537-544.
60. Kavanaugh A, Antoni CE, Gladman D, et al: The infliximab multinational psoriatic arthritis controlled trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006; 65: 1038-1043.
61. Ritchlin CT, Kavanaugh A, Gladman DD, et al: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68: 1387-1394.
62. Baran R, Tosti A: Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatol Treat 1999; 10: 201-204.
63. De Jong EMGJ, Menke HE, van Praag MCG, van de Kerkhof PCM: Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double- blind study. Dermatology 1999; 199: 313-318.
64. Fredriksson T: Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol 1974; 110: 735-736.
65. Kokelj F, Lavaroni G, Piraccini BM, Tosti A: Nail psoriasis treated with calcipotriol (MC 903): an open study. J Dermatol Treat 1994; 5: 149-150.
66. Rigopoulos D, Gregoriou S, Katsambas A: Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol 2007; 87: 167-189.
67. Regana MS, Ezquerra GM, Millet PU, Mateos FL: Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. J Eur Acad Dermatol Venereol 2005; 19: 573-577.
68. Tosti A, Guerra L, Bardazzi F, Lanzarini M: Topical ciclosporin in nail psoriasis. Dermatologica 1990; 180: 110.
69. Yamamoto T, Katayama I, Nishioka K: Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25: 231-233.
70. Saleem K, Azim W: Treatment of nail psoriasis with a modified regimen of steroid injections. J Coll Physicians Surg Pak 2008; 18: 78-81.
71. Arnold WP, Gerritsen MJ, van de Kerkhof PC: Response of nail psoriasis to cyclosporin. Br J Dermatol 1993; 129: 750-751.
72. Feuerman EJ, Nir MA: Allopurinol in psoriasis - a double-blind study. Br J Dermatol 1973; 89: 83-86.
73. Gerster JC: Nail lesions in psoriatic arthritis: recovery with sulfasalazine treatment. Ann Rheum Dis 2002; 61: 277.
74. Lassus A: Colloidal silicic acid for the treatment of psoriatic skin lesions, arthropathy and onychopathy: a pilot study. J Int Med Res 1997; 25: 206-209.
75. Mrowietz U, Christophers E: Low-dose ciclosporin A (Sandimmun- ) in psoriasis: a multicenter dose-finding study. Z Hautkr 1991; 66(suppl 1):25-29.